Patents by Inventor Qinghua Mao

Qinghua Mao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HALOGEN-SUBSTITUTED PYRIDAZINONE COMPOUND AND APPLICATION THEREOF
    Publication number: 20250122190
    Abstract: A halogen-substituted pyridazinone compound and an application thereof. Specifically disclosed is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 9, 2022
    Publication date: April 17, 2025
    Inventors: Xing ZHENG, Qinghua MAO, Tao YU, Chengde WU, Shuhui CHEN
  • Glucoside derivative that acts as SGLT1 inhibitor and application thereof
    Patent number: 12258367
    Abstract: A glucoside derivative that acts as an SGLT1 inhibitor and an application thereof in the preparation of a drug for SGLT1 related diseases. Specifically disclosed is a compound represented by formula (II), a tautomer thereof or a pharmaceutically acceptable composition thereof.
    Type: Grant
    Filed: March 30, 2020
    Date of Patent: March 25, 2025
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Yi Li, Tao Yu, Qinghua Mao, Chengde Wu, Shuhui Chen
  • IMIDAZOCYCLIC COMPOUND AND APPLICATION THEREOF
    Publication number: 20240368178
    Abstract: A series of imidazocyclic compounds and an application thereof, which specifically relate to a compound represented by formula (P) and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 24, 2022
    Publication date: November 7, 2024
    Inventors: Qinghua MAO, Wei WANG, Ye TAN, Bin LIANG, Lu WANG, Chengde WU, Yang ZHANG, Shuhui CHEN
  • CRYSTAL FORM OF SGLT INHIBITOR AND APPLICATION THEREOF
    Publication number: 20220324897
    Abstract: Crystal form A of a compound represented by formula (I) and an application thereof in preparing a drug for treating an SGLT1/SGLT2-related disease.
    Type: Application
    Filed: July 3, 2020
    Publication date: October 13, 2022
    Inventors: Qinghua MAO, Tao YU, Yi LI, Chengde WU, Ting YAO
  • SGLTS/DPP4 INHIBITOR AND APPLICATION THEREOF
    Publication number: 20220259247
    Abstract: A class of compounds as a SGLT1/SGLT2/DPP4 triple inhibitor, and an application in preparation of a drug serving as the SGLT1/SGLT2/DPP4 triple inhibitor. Compounds represented by formula (I), and isomers and pharmaceutically-acceptable salts thereof are specifically involved.
    Type: Application
    Filed: July 24, 2020
    Publication date: August 18, 2022
    Applicant: DONGBAO PURPLE STAR (HANGZHOU) BIOPHARMACEUTICAL CO., LTD.
    Inventors: Qinghua MAO, Tao YU, Yi LI, Chengde WU, Shuhui CHEN
  • SGLT2/DPP4 INHIBITOR AND APPLICATION THEREOF
    Publication number: 20220242898
    Abstract: Compounds as SGLT2/DPP4 dual inhibitors, and application in preparation of medicines as the SGLT2/DPP4 dual inhibitors. A compound represented by formula (I), and an isomer or pharmaceutically acceptable salt thereof are specifically involved.
    Type: Application
    Filed: July 24, 2020
    Publication date: August 4, 2022
    Inventors: Qinghua MAO, Tao YU, Lu GAN, Yi LI, Chengde WU, Shuhui CHEN
  • GLUCOSIDE DERIVATIVE THAT ACTS AS SGLT1 INHIBITOR AND APPLICATION THEREOF
    Publication number: 20220153772
    Abstract: A glucoside derivative that acts as an SGLT1 inhibitor and an application thereof in the preparation of a drug for SGLT1 related diseases. Specifically disclosed is a compound represented by formula (II), a tautomer thereof or a pharmaceutically acceptable composition thereof.
    Type: Application
    Filed: March 30, 2020
    Publication date: May 19, 2022
    Applicant: MEDSHINE DISCOVERY INC.
    Inventors: Yi LI, Tao YU, Qinghua MAO, Chengde WU, Shuhui CHEN
  • Coumarin-like cyclic compound as MEK inhibitor and use thereof
    Patent number: 11021486
    Abstract: Disclosed are a class of coumarin-like cyclic compounds as MEK inhibitors and pharmaceutical compositions comprising the compounds, and the use of same in the preparation of a drug for treating MEK-related diseases. Particularly disclosed are compounds as shown in formula (I) and pharmaceutically acceptable salts thereof or tautomers thereof.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: June 1, 2021
    Assignees: CSTONE PHARMACEUTICALS, CSTONE PHARMACEUTICAL (SUZHOU) CO., LTD., CSTONE PHARMACEUTICALS (SHANGHAI) CO., LTD.
    Inventors: Qinghua Mao, Chengde Wu, Yong Huang, Zhen Gong, Jian Li, Shuhui Chen
  • SGLTS inhibitor and application thereof
    Patent number: 10822365
    Abstract: A compound as an SGLT1/SGLT2 dual inhibitor, and an application thereof in the preparation of a drug as the SGLT1/SGLT2 dual inhibitor. The compound is a compound represented by formula (I), an isomer thereof, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: November 3, 2020
    Inventors: Chengde Wu, Qinghua Mao, Yi Li, Tao Yu, Shuhui Chen
  • SGLTS INHIBITOR AND APPLICATION THEREOF
    Publication number: 20200331950
    Abstract: A compound as an SGLT1/SGLT2 dual inhibitor, and an application thereof in the preparation of a drug as the SGLT1/SGLT2 dual inhibitor. The compound is a compound represented by formula (I), an isomer thereof, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 30, 2020
    Publication date: October 22, 2020
    Inventors: CHENGDE WU, QINGHUA MAO, YI LI, TAO YU, SHUHUI CHEN
  • COUMARIN-LIKE CYCLIC COMPOUND AS MEK INHIBITOR AND USE THEREOF
    Publication number: 20200148695
    Abstract: Disclosed are a class of coumarin-like cyclic compounds as MEK inhibitors and pharmaceutical compositions comprising the compounds, and the use of same in the preparation of a drug for treating MEK-related diseases. Particularly disclosed are compounds as shown in formula (I) and pharmaceutically acceptable salts thereof or tautomers thereof.
    Type: Application
    Filed: June 22, 2018
    Publication date: May 14, 2020
    Applicants: CSTONE PHARMACEUTICALS, CSTONE PHARMACEUTICAL (SUZHOU) CO., LTD., CSTONE PHARMACEUTICALS (SHANGHAI) CO., LTD.
    Inventors: Qinghua MAO, Chengde WU, Yong HUANG, Zhen GONG, Jian LI, Shuhui CHEN
  • TrKA kinase inhibitors, compositions and methods thereof
    Patent number: 9914736
    Abstract: The present invention is directed to substituted five membered heteroaryl benzamide compounds of formula (I) (Formula (I)) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.
    Type: Grant
    Filed: March 23, 2015
    Date of Patent: March 13, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Helen Mitchell, Mark E. Fraley, Andrew J. Cooke, Craig A. Stump, Xu-Fang Zhang, Casey C. McComas, Kathy Schirripa, Melody McWherter, Ping Liu, Dann Parker, Chun Sing Li, Qinghua Mao
  • TrkA kinase inhibitors, compositions and methods thereof
    Patent number: 9896447
    Abstract: The present invention is directed to benzyl urea compounds of formula (I) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence may be useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor Trk-A, Trk-B and/or Trk-C.
    Type: Grant
    Filed: September 17, 2014
    Date of Patent: February 20, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Andrew J. Cooke, Craig A. Stump, Xu-Fang Zhang, Chun Sing Li, Qinghua Mao
  • TRKA kinase inhibitors, compositions and methods thereof
    Patent number: 9862716
    Abstract: The present invention is directed to a bicyclic heteroaryl benzamide compounds of formula (I) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.
    Type: Grant
    Filed: March 23, 2015
    Date of Patent: January 9, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Helen Mitchell, Mark E. Fraley, Andrew J. Cooke, Craig A. Stump, Yi-Heng Chen, Xu-Fang Zhang, Casey C. McComas, Kathy Schirripa, Melody McWherter, Swati P. Mercer, Keith P. Moore, Ping Liu, Harold B. Wood, Chun Sing Li, Qinghua Mao, Douglas C. Beshore
  • TrkA kinase inhibitors, compositions and methods thereof
    Patent number: 9862707
    Abstract: The present invention is directed to a bicyclic heteroaryl benzamide compounds of formula (I) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.
    Type: Grant
    Filed: March 23, 2015
    Date of Patent: January 9, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Helen Mitchell, Harold B. Wood, Chun Sing Li, Qinghua Mao, Zhiqi Qi
  • TrkA kinase inhibitors, compositions and methods thereof
    Patent number: 9815846
    Abstract: The present invention is directed to six membered heteroaryl benzamide compounds of formula (I), which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.
    Type: Grant
    Filed: March 23, 2015
    Date of Patent: November 14, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Helen Mitchell, Mark E. Fraley, Andrew J. Cooke, Craig A. Stump, Yi-Heng Chen, Xu-Fang Zhang, Casey C. McComas, Kathy Schirripa, Melody McWherter, Swati P. Mercer, Kerim Babaoglu, Dongfang Meng, Jane Wu, Ping Liu, Harold B. Wood, Jianming Bao, Chun Sing Li, Qinghua Mao, Zhiqi Qi
  • TrkA kinase inhibitors, compositions and methods thereof
    Patent number: 9718782
    Abstract: The present invention is directed to benzyl urea compounds of formula (I) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence may be useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor Trk-A, Trk-B and/or Trk-C.
    Type: Grant
    Filed: September 17, 2014
    Date of Patent: August 1, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Andrew J. Cooke, Craig A. Stump, Xu-Fang Zhang, Chun Sing Li, Qinghua Mao
  • TrKA Kinase Inhibitors, Compositions and Methods Thereof
    Publication number: 20170158698
    Abstract: The present invention is directed to substituted five membered heteroaryl benzamide compounds of formula (I) (Formula (I)) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.
    Type: Application
    Filed: March 23, 2015
    Publication date: June 8, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Helen Mitchell, Mark E. Fraley, Andrew J. Cooke, Craig A. Stump, Xu-Fang Zhang, Casey C. McComas, Kathy Schirripa, Melody McWherter, Ping Liu, Dann Parker, Chun Sing Li, Qinghua Mao
  • TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
    Publication number: 20170114056
    Abstract: The present invention is directed to a bicyclic heteroaryl benzamide compounds of formula (I) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.
    Type: Application
    Filed: March 23, 2015
    Publication date: April 27, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Helen Mitchell, Mark E. Fraley, Andrew J. Cooke, Craig A. Stump, Yi- Heng Chen, Xu-Fang Zhang, Casey C. McComas, Kathy Schirripa, Melody McWherter, Swati P. Mercer, Keith P. Moore, Ping Liu, Harold B. Wood, Chun Sing Li, Qinghua Mao, Douglas C. Beshore
  • TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
    Publication number: 20170114071
    Abstract: The present invention is directed to six membered heteroaryl benzamide compounds of formula (I), which are tropomyosin-related kinase (Trk) family protein pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.
    Type: Application
    Filed: March 23, 2015
    Publication date: April 27, 2017
    Applicants: Merck Sharp & Dohme Corp., MSD R & D (China) Co., LTD.
    Inventors: Helen Mitchell, Mark E. Fraley, Andrew J. Cooke, Craig A. Stump, Yi- Heng Chen, Xu-Fang Zhang, Casey C. McComas, Kathy Schirripa, Melody McWherter, Swati P. Mercer, Kerim Babaoglu, Dongfang Meng, Jane Wu, Ping Liu, Harold B. Wood, Jianming Bao, Chun Sing Li, Qinghua Mao, Zhiqi Qi